Hematologic Malignancies Congress

Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS

Certain characteristics of patients with CML can affect therapeutic outcomes.

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Dr. Stephen Ansell from the Mayo Clinic Describes Waldenström Macroglobulinemia